Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review

  title={Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review},
  author={James M. Stone and Paul D. Morrison and Lyn S. Pilowsky},
  journal={Journal of Psychopharmacology},
  pages={440 - 452}
The dopamine hypothesis of schizophrenia is the principal explanatory model of antipsychotic drug action. Recent discoveries extend our understanding of the neurochemistry of schizophrenia, with increasing evidence of dysfunction in glutamate and GABA as well as dopamine systems. In this review, we study the evidence for dopaminergic dysfunction in schizophrenia, drawing data from neurochemical imaging studies. We also review the NMDA receptor hypofunction hypothesis of schizophrenia as a… 

Figures from this paper

Glutamate and dopamine in schizophrenia: An update for the 21st century

This review provides an update on the latest findings on dopamine and glutamate abnormalities in schizophrenia, focusing on in vivo neuroimaging studies in patients and clinical high-risk groups, and considers their implications for understanding the biology and treatment of schizophrenia.

Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications

It is proposed that metabotropic glutamate receptors can have a modulatory effect over the NMDAR and regulate excitotoxity mechanisms and constitute a highly promising target for future drug treatment in this disease.

Beyond Dopamine: Glutamate as a Target for Future Antipsychotics

Recent findings integrating glutamatergic and dopaminergic abnormalities in schizophrenia and their implications for novel pharmacological targets are discussed and their potential future role in the pharmacotherapy of schizophrenia is critically evaluated.

The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged.

4 lines of evidence support the hypothesis that glutamate deregulation, mainly through dysfunction of the N-methyl-D-aspartate (NMDA) receptor, is an important underlying mechanism of schizophrenia.

Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development

Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?

  • J. Stone
  • Psychology, Medicine
    Therapeutic advances in psychopharmacology
  • 2011
It has been hypothesized that glutamatergic drugs may be of benefit to the 20–30% of individuals with schizophrenia who fail to show any response to dopaminergic agents, and may be particularly useful in the early stages of the illness, where they may be disease-modifying.

From glutamatergic dysfunction to cognitive impairment: boundaries in the therapeutic of the schizophrenia.

The role of certain chemical families as potential sources of new lead compounds with affinity for metabotropic glutamate receptors (mGluRs) with cognitive enhancing properties are emphasized and new insights into their potential role in developing pharmacological treatments are provided.

Glutamatergic Neurotransmission Abnormalities and Schizophrenia

Evidence showing that N-methyl-d-aspartate receptor hypofunction may be crucial in the pathophysiological features of schizophrenia is described and therapeutic agents directed toward glutamatergic systems may be helpful in the treatment of positive and negative symptoms and cognitive deficits associated with schizophrenia.

Antipsychotic treatment modulates glutamate transport and NMDA receptor expression

This review summarizes the current knowledge on effects of FGAs and SGAs on glutamate transport and receptor expression derived from pharmacological studies and indicates that serotonergic effects of SGAs represent important targets for further clinical research.



Glutamate receptor dysfunction and schizophrenia.

It is proposed that since N-methyl-D-aspartate receptor hypofunction can cause psychosis in humans and corticolimbic neurodegenerative changes in the rat brain, and since these changes are prevented by certain antipsychotic drugs, including atypical neuroleptic agents, a better understanding of this mechanism may lead to improved pharmacotherapy in schizophrenia.

Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia

There is convincing evidence that hypofunction of a subset of NMDA receptors may contribute to the symptomatic features of schizophrenia.

Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia

  • A. Abi-DarghamH. Moore
  • Psychology, Medicine
    The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry
  • 2003
Current evidence for prefrontal hypodopaminergia in schizophrenia is reviewed, with special emphasis on positron emission tomography studies measuring cortical D1 receptors in schizophrenia, and the formulation of several models of altered prefrontal DA transmission at D1 receptor in schizophrenia are considered.

NMDA receptor hypofunction model of schizophrenia.

Glutamate receptor expression in schizophrenic brain

Cholinergic aspects of schizophrenia

  • R. Tandon
  • Psychology, Medicine
    British Journal of Psychiatry
  • 1999
The use of anticholinergic agents to treat extrapyramidal side-effects and the fact that many antipsychotic agents have intrinsic anti-cholinergic activity suggest that the role of the cholinergic system in schizophrenia needs to be more clearly delineated.

Synaptic Plasticity and Dysconnection in Schizophrenia

Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities

Using animal models to test a neurodevelopmental hypothesis of schizophrenia.

  • B. Lipska
  • Psychology, Biology
    Journal of psychiatry & neuroscience : JPN
  • 2004
The data suggest that neonatal disconnection of the ventral hippocampus alters development and plasticity of prefrontal cortical circuitry and produces a constellation of behavioural and cellular changes that mimic many aspects of schizophrenia.